A detailed history of Larson Financial Group LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Larson Financial Group LLC holds 154 shares of PTGX stock, worth $13,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares
154
Previous 26 492.31%
Holding current value
$13,029
Previous $1,000 900.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$49.7 - $67.42 $6,361 - $8,629
128 Added 492.31%
154 $10,000
Q2 2025

Aug 08, 2025

SELL
$40.89 - $56.37 $4,089 - $5,637
-100 Reduced 79.37%
26 $1,000
Q1 2025

May 02, 2025

BUY
$35.09 - $59.76 $3,894 - $6,633
111 Added 740.0%
126 $6,000
Q4 2024

Feb 07, 2025

SELL
$38.51 - $48.43 $77 - $96
-2 Reduced 11.76%
15 $0
Q3 2024

Nov 12, 2024

BUY
$33.72 - $47.33 $573 - $804
17 New
17 $0

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $4.15B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.